Nielsen Kirk G. 4

What Happened
Kirk G. Nielsen, a reported 10% owner of SpyGlass Pharma, was granted 27,400 derivative shares (award code A) on February 5, 2026 at an acquisition price of $0.00. The award is subject to vesting and is reported as a derivative grant rather than an open-market purchase or sale.

Key Details

• Transaction date: February 5, 2026; Form 4 filed February 9, 2026. Filing does not indicate delinquency.
• Grant: 27,400 derivative shares reported at $0.00 per share.
• Shares owned after transaction: Not specified in this filing.
• Vesting footnote: Shares vest 1/36th each month following the grant date (Date of Grant = Feb 5, 2026), contingent on Nielsen continuing as an Outside Director under the issuer’s 2026 Equity Incentive Plan.
• Transaction type: Award/Grant of a derivative security (code A).

Context
This was a grant of a derivative award (likely restricted shares or units subject to vesting), not a sale or open-market purchase. As a 10% owner and Outside Director, Nielsen’s award is tied to continued service and vests monthly over three years, so the grant does not reflect an immediate change in market holdings or a cash transaction.